Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Recruiting now
Conditions studied: Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Liver Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Skin Neoplasm, Metastatic Malignant Solid Neoplasm, Resectable Lung Non-Small Cell Carcinoma, Early Stage Lung Non-Small Cell Carcinoma, Resectable Malignant Solid Neoplasm, Resectable Triple-Negative Breast Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Recurrent Cervical Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Solid Neoplasm
In brief
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
Key facts
- Study ID
- NCT06349642
- Run by
- Mayo Clinic
- People needed
- 324
- Starts
- 2024-04-24
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2026-03-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subjects must meet one of the following criteria:
- Subjects suspected of or diagnosed with the following Stage IV/metastatic or recurrent malignancies:
- Lung: Non-small Cell Lung Cancer (NSCLC)
- Skin: Cutaneous Malignancy, excluding Uveal Melanoma
- Esophageal Cancer
- Cervical Cancer
- Endometrial Cancer
- Colon Cancer: Mismatch repair deficient (dMMR) CRC only
- All solid tumors with high tumor mutation burden (TMB)
- All solid tumors that are microsatellite instability high (MSI-H)
- All mismatch repair deficient (dMMR) solid tumors
- Liver Cancer
- Any solid tumor with measurable disease that is eligible for pure ICI therapy or that the clinician plans to treat with immune checkpoint inhibitor (ICI) therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate laboratory developed tests (LDTs) that, per clinician, render the patient eligible for ICI therapy, either frontline or a later line.
- OR
- Subjects suspected of or diagnosed with the following Stage III per provider discretion or IV/metastatic malignancies:
- Kidney: Clear Cell Renal Cell Carcinoma (ccRCC)
- Bladder: Urothelial Carcinoma (UC)
- Any solid tumor with measurable disease that is eligible for pure ICI therapy or that the clinician plans to treat with ICI therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate LDT tests that per clinician, render the patient eligible for ICI therapy, either frontline or a later line
- OR
- Patients who will be receiving neoadjuvant CPI for the following resectable early-stage malignancies:
- Breast Cancer: Triple negative breast cancer (TNBC)
- Lung: Non-small cell lung cancer (NSCLC)
- NOTE: Patients with suspected NSCLC who would be eligible for neoadjuvant checkpoint inhibitor (CPI) are eligible to enroll per provider discretion
- Any solid tumor that is eligible for pure ICI therapy or that the clinician plans to treat with ICI therapy. NOTE: This can be in the setting of a trial, compassionate use, or the use of appropriate LDT tests that per clinician, render the patient eligible for ICI therapy, either frontline or a later line
- LOCALLY ADVANCED/METASTATIC PATIENTS: Measurable disease as defined per protocol NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible.
You may not qualify if…
- Pregnant women because this study involves a greater than minimal risk procedure (biopsy)
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety for the biopsy
- Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy
- NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
- Uncontrolled intercurrent illness including, but not limited to:
- ongoing or active infection
- psychiatric illness/social situations that would limit compliance with study requirements
- Subjects who are enrolled or plan to be enrolled in a blinded cancer therapeutic treatment trial
Where it is running
- Mayo Clinic in Arizona — Phoenix, Arizona, United States (enrolling)
- Mayo Clinic in Florida — Jacksonville, Florida, United States (enrolling)
- Mayo Clinic in Rochester — Rochester, Minnesota, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.